Browsing by Author "Stojanović-Rundić, Suzana (23037160700)"

Introduction Colorectal cancer is the third most common cancer and one of the leading causes of cancer-related deaths in men and women worldwide. The contemporary multidisciplinary approach has decreased rates of local recurrence and improved outcomes in metastatic colorectal cancer. We present a case of a primarily metastatic rectal cancer patient who underwent multidisciplinary planned treatment and showed complete response with now three years disease-free survival. Case outline A 61-year-old female was diagnosed with a T4N2M1a rectal adenocarcinoma at the age of 58. She underwent six cycles of systemic chemotherapy capecitabine-oxaliplatin plus bevacizumab with partial response confirmed by diagnostic imaging procedures. According to multidisciplinary board decision, preoperative radiotherapy treatment was administered with concomitant capecitabinebased chemotherapy. A 50.4 Gy total dose was delivered with 1.8 Gy fraction dose. After concomitant chemoradiotherapy treatment, two more cycles of systemic chemotherapy capecitabine-oxaliplatin plus bevacizumab were administered. One month after completion of systemic chemotherapy, primary rectal cancer was operated with a complete response on histopathologic specimens. Six weeks following previous surgery, metastasectomy of lung deposits was performed; histopathology confirmed metastatic adenocarcinoma of colorectal origin. Three more cycles of postoperative chemotherapy capecitabine-oxaliplatin plus bevacizumab were administered. Conclusion On regular follow-up, no evidence of disease was shown, with disease-free survival of three years. The treatment improved the patient’s quality of life. © 2021, Serbia Medical Society. All rights reserved.

Treatment of gastroesophageal junction carcinomas have been debated for many years. This type of carcinomas has been classified as either gastric or esophageal carcinomas until Siewert’s classification was established and they were defined as a distinct entity. Risk factors for the development of these cancers are gastroesophageal reflux and Barrett’s esophagus, obesity, Helycobacter pylori infection, smok-ing, and alcohol. Symptoms of this disease include retrosternal pain, dysphagia to aphagia, and weight loss. Esophagogastroduodenoscopy with biopsy and pathohistological verification as well as CT of the chest and abdomen are crucial in establishing the diagnosis. Adenocarcinoma is predominant histo-logical type of these tumors. The stage of the disease is defined by the TNM classification. Treatment of gastroesophageal junction cancer is complex, multidisciplinary, and multimodal, and involves the use of surgery, chemotherapy, and radiotherapy, alone or in different combinations. Surgery is the major treatment modality for these tumors, especially in local stages. Radiotherapy is used in the treatment of these tumors in all stages of the disease, and especially in the multimodal treatment of locally advanced gastroesophageal junction cancer, both preoperatively and postoperatively, usually in combination with chemotherapy. Chemotherapy is used in the treatment of these cancers as preoperative, postoperative and systemic. Immunotherapy and target therapy, as new promising therapy, is usually applied in a systemic and postoperative approach. Future directions in the treatment of these cancers are directed towards new surgical procedures, new types of immunotherapy, as well as new radiotherapy techniques. © 2024, Serbia Medical Society. All rights reserved.

Pancreatic cancer is one of the most aggressive tumors and is among the top ten most common malignan-cies in the world. This is a disease of older adults, and men get it more often. Pancreatic carcinomas risk factors are obesity and type II diabetes, smoking, and alcohol consumption. Symptoms of the disease in-clude obstructive jaundice, loss of appetite, weight loss, fatigue, and back pain. The diagnosis of pancreatic cancer involves computed tomography of the thorax, abdomen and pelvis or magnetic resonance imaging of the abdomen and pelvis, and endoscopic ultrasound with biopsy. The most common histological type of pancreatic cancer is ductal adenocarcinoma. The TNM classification is used to determine the stage of the disease. Pancreatic cancer treatment is complex, multidisciplinary, and multimodal, and involves the use of surgery, chemotherapy, and radiotherapy, alone or in different combinations. Surgery is the main treatment modality for these tumors, especially in localized stages. Chemotherapy is applied in all forms in the treatment of pancreatic cancer as neoadjuvant, adjuvant, and systemic. Immunotherapy, as the newest type of treatment, is used in a limited way in the metastatic phase of pancreatic cancer. The role of radiotherapy in the treatment of pancreatic cancer is still debated, and it is most often applied in a neoadjuvant and palliative approach. Palliative therapy and care are an indispensable part of the treatment of patients with pancreatic cancer. © 2024, Serbia Medical Society. All rights reserved.